乳腺癌40年的研究与进展
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Advances in Breast Cancer Management and Research between 1970s - Present
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Systemic Management of Primary Breast Cancer
Systemic Management of Metastatic Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Management of ER+ Metastatic Breast Cancer in Postmenopausal Women in a Few Weeks…
2000s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 36
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 37
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Endocrine Therapy (2)
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Breast Cancer Research Themes – 1970s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Advances in Breast Cancer Management and Research between 1970s - Present
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer Treatment in the 20th Century:<br />Quest for the Ideal Local-regional Therapy
Breast Cancer Molecuபைடு நூலகம்ar Subtypes
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 41
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
NeoAdjuvant Chemotherapy
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
1980s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
10-year Outcome in Polychemotherapy Trials, Subdivided by Nodal Status
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Endocrine Therapy
Supportive Care
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer Research Themes – 1980s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Chemotherapy
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 12
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Management of Patients with Stage IV NED Breast Cancer (Oligometastases)
Comprehensive molecular portraits of human breast tumours
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Combined Endocrine and Pathway Inhibitor Therapy for MBC
Development of combined endocrine therapy<br />(Selected articles from a list of >1100 peer-reviewed publications)
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Incorporation of Bisphosphonates in the Management of Bone Metastases in Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Evaluation of New Antitumor Agents
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
1980s: Improvements in Diagnosis and Management
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Personal Contributions
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Chemotherapy
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Targeted Therapies
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Trastuzumab Trials<br />Disease-free Survival
The death rate for female breast cancer dropped by 40% from 1989 to 2016.
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Technological Progress
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Randomized Trials with cdk4/6-Inhibitors in First-Line Metastatic, HR+ Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
1990s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Development of New Drugs for Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer: 40 Years of Research and Progress
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
A Gallery of Giants
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer Management<br />Standard of Care - 1974
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Towards Personalized Breast Oncology
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Development of Gene Expression Profiling in Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Development of gene expression profiling<br />(Selected articles from a list of >1100 peer-reviewed publications)
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
2-Year Absolute Benefit from Trastuzumab vs. Not: <br /><br />Recurrence: 6%-12% <br /> Logrank 2p < 0.001<br />Mortality: 2%-6%<br /> Logrank 2p 0.004-0.07
Advances in Breast Cancer Management and Research between 1970s - Present
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Systemic Management of Primary Breast Cancer
Systemic Management of Metastatic Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Management of ER+ Metastatic Breast Cancer in Postmenopausal Women in a Few Weeks…
2000s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 36
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 37
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Endocrine Therapy (2)
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Breast Cancer Research Themes – 1970s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Advances in Breast Cancer Management and Research between 1970s - Present
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer Treatment in the 20th Century:<br />Quest for the Ideal Local-regional Therapy
Breast Cancer Molecuபைடு நூலகம்ar Subtypes
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 41
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
NeoAdjuvant Chemotherapy
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
1980s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
10-year Outcome in Polychemotherapy Trials, Subdivided by Nodal Status
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Endocrine Therapy
Supportive Care
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer Research Themes – 1980s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Chemotherapy
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Slide 12
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Management of Patients with Stage IV NED Breast Cancer (Oligometastases)
Comprehensive molecular portraits of human breast tumours
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Combined Endocrine and Pathway Inhibitor Therapy for MBC
Development of combined endocrine therapy<br />(Selected articles from a list of >1100 peer-reviewed publications)
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Incorporation of Bisphosphonates in the Management of Bone Metastases in Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Evaluation of New Antitumor Agents
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
1980s: Improvements in Diagnosis and Management
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Personal Contributions
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Chemotherapy
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Targeted Therapies
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Adjuvant Trastuzumab Trials<br />Disease-free Survival
The death rate for female breast cancer dropped by 40% from 1989 to 2016.
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Technological Progress
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Randomized Trials with cdk4/6-Inhibitors in First-Line Metastatic, HR+ Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
1990s
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Development of New Drugs for Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
History of Breast Cancer Treatment<br />Timeline
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer: 40 Years of Research and Progress
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
A Gallery of Giants
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Breast Cancer Management<br />Standard of Care - 1974
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Towards Personalized Breast Oncology
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Development of Gene Expression Profiling in Breast Cancer
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
Development of gene expression profiling<br />(Selected articles from a list of >1100 peer-reviewed publications)
Presented By Gabriel Hortobagyi at 2019 ASCO Annual Meeting
2-Year Absolute Benefit from Trastuzumab vs. Not: <br /><br />Recurrence: 6%-12% <br /> Logrank 2p < 0.001<br />Mortality: 2%-6%<br /> Logrank 2p 0.004-0.07